EP2574333A1 — N-acetylcysteine effervescent tablet and its therapeutical applications
Assigned to Friulchem SpA · Expires 2013-04-03 · 13y expired
What this patent protects
The present invention is directed to A pharmaceutical composition in the form of an effervescent tablet comprising: (a) 1200 mg ofN-acetylcysteine; and (b) at least 1200 mg of sodium hydrogen carbonate; and (c) less than 1200 mg of anhydrous citric acid; and (d) at least one …
USPTO Abstract
The present invention is directed to A pharmaceutical composition in the form of an effervescent tablet comprising: (a) 1200 mg ofN-acetylcysteine; and (b) at least 1200 mg of sodium hydrogen carbonate; and (c) less than 1200 mg of anhydrous citric acid; and (d) at least one lubricant and/or glidant agent; and (e) at least one sweetener and/or flavouring agent; and said pharmaceutical composition having no sulfur smell and taste as well as a pH in the range of 4.1 and 4.4 after tablet dissolution. A manufacturing process is also disclosed. The claimed pharmaceutical composition is used in the treatment of abnormal, viscid, or inspissated mucous secretions.
Drugs covered by this patent
- Acetadote (Acetylcysteine) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.